Investigational drug · Phase 2
SAR444336
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Microscopic Colitis.
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "SAR444336"
First trial start
2025
Oct 14, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "SAR444336", any sponsor or status.
Conditions studied
As listed on its trial records.
- Microscopic Colitis
Largest trials
Live from ClinicalTrials.gov: studies naming "SAR444336" as an intervention, largest first.
SanofiSanofi (SNY)
NCT05876767 · 76 participants · Start Oct 15, 2021 · Primary completion Dec 12, 2023
Drug: SAR444336; Placebo · For: Healthy Volunteer
Sites: Leiden, Netherlands; Groningen, Netherlands
- A Study to Investigate the Efficacy and Safety of SAR444336 in Adults With Microscopic Colitis in Clinical RemissionActive, not recruiting
SanofiSanofi (SNY)
NCT07156175 · 60 participants · Start Oct 14, 2025 · Primary completion Apr 8, 2027
Drug: SAR444336; Placebo · For: Microscopic Colitis
Sites: Leuven, Belgium; Aarhus, Denmark; Hvidovre, Denmark · 24 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- The IL-2 SYNTHORIN molecule promotes functionally adapted Tregs in a preclinical model of type 1 diabetes.
Alvarez F, Acuff NV, La Muraglia GM, et al. · JCI Insight 2024
- A CD25-biased interleukin-2 for autoimmune therapy engineered via a semi-synthetic organism.
Ptacin JL, Ma L, Caffaro CE, et al. · Commun Med (Lond) 2024
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Sanofi.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.